Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04037254
Other study ID # NRG-GU007
Secondary ID NCI-2019-02260NR
Status Suspended
Phase Phase 2
First received
Last updated
Start date June 3, 2019
Est. completion date December 31, 2028

Study information

Verified date February 2024
Source NRG Oncology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies the side effects and best dose of niraparib, and to see how well it works in combination with standard of care radiation therapy and hormonal therapy (androgen deprivation therapy) in treating patients with prostate cancer that has a high chance of coming back (high risk). Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding niraparib to the usual treatments of radiation therapy and hormonal therapy may lower the chance of prostate cancer growing or returning.


Description:

PRIMARY OBJECTIVES: I. To establish the preferred dose of niraparib in combination with radiation and antiandrogen therapy (ADT). (Phase I) II. To compare the disease-free state, defined as PSA remaining < 0.1 ng/ml at the end of ADT therapy in men with high risk prostate cancer treated with standard therapy with or without the addition of niraparib. (Phase IIR) SECONDARY OBJECTIVES: I. To further establish the safety and toxicity profile of standard treatment with radiation and androgen deprivation therapy specifically, two years from initiation of ADT, plus niraparib at the phase II dose. II. To compare the overall survival, prostate cancer-specific survival, local/regional or distant progression, and distant metastatic disease rates of standard therapy with or without the addition of niraparib. EXPLORATORY OBJECTIVES: I. To identify genomic biomarkers of response to combination therapy with radiation, ADT and PARP inhibition. OUTLINE: This is a phase I, dose-escalation study of niraparib, followed by a phase II study. PHASE I: Patients receive niraparib orally (PO) once daily (QD) and receive standard of care gonadotrophin releasing hormone (GnRH) agonist androgen suppression therapy. Treatment with niraparib continues for 12 months, and GnRH agonist therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib and GnRH agonist, patients undergo standard of care intensity-modulated radiation therapy (IMRT) 5 days per week for about 6-9 weeks, depending on type of radiation therapy given, in the absence of disease progression or unacceptable toxicity. PHASE II: Patients are randomized to 1 of 2 arms: ARM I: Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8-28 weeks after starting GnRH agonist, patients undergo IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity. ARM II: Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months, and niraparib PO QD for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for 3 years, then annually for 3 years.


Recruitment information / eligibility

Status Suspended
Enrollment 180
Est. completion date December 31, 2028
Est. primary completion date January 30, 2028
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed (within 180 days prior to registration) adenocarcinoma of the prostate at high risk for recurrence as determined by the following criteria, according to American Joint Committee on Cancer (AJCC) 8th edition: - Phase I enrollment - Gleason = 9, PSA = 150 ng/mL, any T-stage - Phase II enrollment - Gleason = 9, PSA = 150 ng/mL, any T-stage - Gleason 8, PSA < 20 ng/mL, and = T2 - Gleason 8, PSA = 20-150 ng/mL, any T-stage - Gleason 7, PSA = 20-150 ng/mL, any T-stage - No distant metastases as evaluated by: - Bone scan 90 days prior to registration - Lymph node assessment by computed tomography (CT) or magnetic resonance (MR) of pelvis or nodal sampling within 90 days prior to registration (Please note: Lymph nodes will be considered negative (N0) if they are < 1.5 cm short axis) - History/physical examination within 90 days prior to registration - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 180 days prior to registration - Pretreatment serum PSA, obtained prior to any androgen suppression therapy and within 180 days of registration - Phase I patients: Prior androgen suppression for prostate cancer is not allowed prior to registration - Phase II patients: Prior androgen suppression for prostate cancer is allowed = 45 days prior to registration - Hemoglobin = 9.0 g/dL (within 90 days prior to registration) - Platelets = 100,000 cells/mm^3 (within 90 days prior to registration) - Absolute neutrophil count (ANC) = 1.5 x 10^9/L (within 90 days prior to registration) - Serum creatinine =1.5 x upper limit of normal (ULN) OR a calculated creatinine clearance >= 30 mL/min estimated using Cockcroft-Gault equation (within 90 days prior to registration) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 x ULN (within 90 days prior to registration) - Serum albumin = 3 g/dL (within 90 days prior to registration) - Serum potassium = 3.5 mmol/L (within 90 days prior to registration) - Serum total bilirubin = 1.5 x ULN or direct bilirubin = 1 x ULN (Note: in subjects with Gilberts syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin, and if direct bilirubin is = 1.5 x ULN, subject may be eligible) (within 90 days prior to registration) - Men of child-producing potential must be willing to consent to use effective contraception while on treatment and for at least 3 months afterwards - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry Exclusion Criteria: - PSA > 150 ng/mL - Definitive clinical or radiologic evidence of metastatic disease - Pathologically positive lymph nodes or nodes > 1.5 cm short axis on CT or MR imaging - Prior radical prostatectomy, cryosurgery for prostate cancer, or bilateral orchiectomy for any reason - Any active malignancy within 2 years of study registration that may alter the course of prostate cancer treatment. - Prior systemic therapy for prostate cancer; note that prior therapy for a different cancer is allowable - Prior radiotherapy, including brachytherapy, to the region of the prostate that would result in overlap of radiation therapy fields - Current treatment with first generation anti-androgens (bicalutamide, nilutamide, flutamide). For patients enrolled to phase II, if prior anti-androgens were administered, a washout period of >= 30 days is required prior to enrollment - Severe, active co-morbidity, defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months - Transmural myocardial infarction within the last 6 months - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration - Uncontrolled acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition - Presence of uncontrolled hypertension (persistent systolic blood pressure [BP] >=160 mmHg or diastolic BP >= 100 mmHg). Subjects with a history of hypertension are allowed, provided that BP is controlled to within these limits by anti-hypertensive treatment - Prior allergic reaction to the drugs involved in this protocol (including known allergies, hypersensitivity or intolerance to the excipients of niraparib. Please see Niraparib IB for details.) - Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter - Note that patients who are HIV positive are eligible, provided they have a CD4 count >= 200 cells/microliter within 90 days prior to registration. Patients receiving treatment with highly active antiretroviral therapy (HAART) will not be eligible due to concern for radiosensitization - Note also that HIV testing is not required for eligibility for this protocol. This exclusion criterion is necessary because the treatments involved in this protocol may be affected by these drugs. - Any history or current diagnosis of Myelodysplasitc Syndromes (MDS)/ Acute Myeloid Leukemia (AML). - Prior or current treatment with PARP inhibitor

Study Design


Related Conditions & MeSH terms

  • Prostate Adenocarcinoma
  • Prostatic Neoplasms
  • Stage IIC Prostate Cancer AJCC v8
  • Stage III Prostate Cancer AJCC v8
  • Stage IIIA Prostate Cancer AJCC v8
  • Stage IIIB Prostate Cancer AJCC v8
  • Stage IIIC Prostate Cancer AJCC v8
  • Stage IVA Prostate Cancer AJCC v8

Intervention

Biological:
Gonadotrophin Releasing Hormone
Receive standard of care GnRH agonist androgen suppression therapy
Radiation:
Intensity-Modulated Radiation Therapy
Undergo standard of care IMRT
Drug:
Niraparib
Given PO

Locations

Country Name City State
Canada Tom Baker Cancer Centre Calgary Alberta
United States Summa Health System - Akron Campus Akron Ohio
United States Alton Memorial Hospital Alton Illinois
United States Emory Saint Joseph's Hospital Atlanta Georgia
United States Emory University Hospital/Winship Cancer Institute Atlanta Georgia
United States Grady Health System Atlanta Georgia
United States University of Maryland/Greenebaum Cancer Center Baltimore Maryland
United States Summa Health System - Barberton Campus Barberton Ohio
United States McLaren Cancer Institute-Bay City Bay City Michigan
United States Massachusetts General Hospital Cancer Center Boston Massachusetts
United States Henry Ford Cancer Institute-Downriver Brownstown Michigan
United States Roswell Park Cancer Institute Buffalo New York
United States AtlantiCare Health Park-Cape May Court House Cape May Court House New Jersey
United States Christiana Care Health System-Concord Health Center Chadds Ford Pennsylvania
United States Medical University of South Carolina Charleston South Carolina
United States Northwestern University Chicago Illinois
United States Rush University Medical Center Chicago Illinois
United States University of Cincinnati Cancer Center-UC Medical Center Cincinnati Ohio
United States McLaren Cancer Institute-Clarkston Clarkston Michigan
United States Case Western Reserve University Cleveland Ohio
United States Henry Ford Macomb Hospital-Clinton Township Clinton Township Michigan
United States Central Maryland Radiation Oncology in Howard County Columbia Maryland
United States Siteman Cancer Center at West County Hospital Creve Coeur Missouri
United States Geisinger Medical Center Danville Pennsylvania
United States Henry Ford Medical Center-Fairlane Dearborn Michigan
United States Henry Ford Hospital Detroit Michigan
United States Wayne State University/Karmanos Cancer Institute Detroit Michigan
United States City of Hope Comprehensive Cancer Center Duarte California
United States AtlantiCare Surgery Center Egg Harbor Township New Jersey
United States Weisberg Cancer Treatment Center Farmington Hills Michigan
United States McLaren Cancer Institute-Flint Flint Michigan
United States Singh and Arora Hematology Oncology PC Flint Michigan
United States The New York Hospital Medical Center of Queens Flushing New York
United States Banner MD Anderson Cancer Center Gilbert Arizona
United States UM Baltimore Washington Medical Center/Tate Cancer Center Glen Burnie Maryland
United States Benefis Healthcare- Sletten Cancer Institute Great Falls Montana
United States Prisma Health Cancer Institute - Eastside Greenville South Carolina
United States Prisma Health Cancer Institute - Faris Greenville South Carolina
United States Saint Francis Cancer Center Greenville South Carolina
United States Self Regional Healthcare Greenwood South Carolina
United States Prisma Health Cancer Institute - Greer Greer South Carolina
United States Penn State Milton S Hershey Medical Center Hershey Pennsylvania
United States University of Iowa/Holden Comprehensive Cancer Center Iowa City Iowa
United States University of Mississippi Medical Center Jackson Mississippi
United States University of Kansas Cancer Center Kansas City Kansas
United States University of Kansas Cancer Center - North Kansas City Missouri
United States Karmanos Cancer Institute at McLaren Greater Lansing Lansing Michigan
United States Mid-Michigan Physicians-Lansing Lansing Michigan
United States McLaren Cancer Institute-Lapeer Region Lapeer Michigan
United States University of Kansas Cancer Center - Lee's Summit Lee's Summit Missouri
United States Geisinger Medical Oncology-Lewisburg Lewisburg Pennsylvania
United States Lewistown Hospital Lewistown Pennsylvania
United States Cedars Sinai Medical Center Los Angeles California
United States Fremont - Rideout Cancer Center Marysville California
United States Summa Health Medina Medical Center Medina Ohio
United States Froedtert Menomonee Falls Hospital Menomonee Falls Wisconsin
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Zablocki Veterans Administration Medical Center Milwaukee Wisconsin
United States West Virginia University Healthcare Morgantown West Virginia
United States McLaren Cancer Institute-Macomb Mount Clemens Michigan
United States Helen F Graham Cancer Center Newark Delaware
United States Medical Oncology Hematology Consultants PA Newark Delaware
United States Rutgers New Jersey Medical School Newark New Jersey
United States CTCA at Southeastern Regional Medical Center Newnan Georgia
United States Henry Ford Medical Center-Columbus Novi Michigan
United States Drexel Town Square Health Center Oak Creek Wisconsin
United States ProHealth Oconomowoc Memorial Hospital Oconomowoc Wisconsin
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States University of Kansas Cancer Center-Overland Park Overland Park Kansas
United States McLaren Cancer Institute-Northern Michigan Petoskey Michigan
United States Eastern Regional Medical Center Philadelphia Pennsylvania
United States University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania
United States UPMC-Shadyside Hospital Pittsburgh Pennsylvania
United States McLaren-Port Huron Port Huron Michigan
United States Highland Hospital Rochester New York
United States University of Rochester Rochester New York
United States University of California Davis Comprehensive Cancer Center Sacramento California
United States Siteman Cancer Center-South County Saint Louis Missouri
United States Washington University School of Medicine Saint Louis Missouri
United States Siteman Cancer Center at Saint Peters Hospital Saint Peters Missouri
United States Prisma Health Cancer Institute - Seneca Seneca South Carolina
United States Henry Ford Macomb Health Center - Shelby Township Shelby Michigan
United States Stony Brook University Medical Center Stony Brook New York
United States Holy Name Hospital Teaneck New Jersey
United States University of Arizona Cancer Center-North Campus Tucson Arizona
United States University of Arizona Cancer Center-Orange Grove Campus Tucson Arizona
United States City of Hope Upland Upland California
United States Carle Cancer Center Urbana Illinois
United States George Washington University Medical Center Washington District of Columbia
United States UW Cancer Center at ProHealth Care Waukesha Wisconsin
United States Froedtert West Bend Hospital/Kraemer Cancer Center West Bend Wisconsin
United States Henry Ford West Bloomfield Hospital West Bloomfield Michigan
United States University of Cincinnati Cancer Center-West Chester West Chester Ohio
United States University of Kansas Hospital-Westwood Cancer Center Westwood Kansas
United States Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
NRG Oncology National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Exome sequencing of deoxyribonucleic acid (DNA) repair genes and detected alterations Descriptive statistics will be generated summarizing the frequency of gene alterations, mutations, and gene expression levels. The percentage of patients with baseline or post-therapy alterations in targeted genes will be reported and the association between the occurrence of reversion mutations in DNA repair genes and clinical outcomes will be assessed using logistic regression models for dichotomous endpoints (disease-free state, pCR), and Cox regression or competing risk regression modeling for time-to-event data. Up to 3 years
Other Transcription-wide analysis of gene expression Will be assessed using a high-density Affymetrix oligonucleotide array to profile the transcriptome of tumor samples. Descriptive statistics will be generated summarizing the frequency of gene alterations, mutations, and gene expression levels. The percentage of patients with baseline or post-therapy alterations in targeted genes will be reported and the association between the occurrence of reversion mutations in DNA repair genes and clinical outcomes will be assessed using logistic regression models for dichotomous endpoints (disease-free state, pCR), and Cox regression or competing risk regression modeling for time-to-event data. Up to 3 years
Other Single nucleotide polymorphisms Will be analyzed in whole blood samples previously associated with prostate risk. Plasma samples will be assessed for baseline and post-therapy alterations in a targeted gene panel and for reversion mutations in DNA repair genes as early biomarkers of treatment resistance. Descriptive statistics will be generated summarizing the frequency of gene alterations, mutations, and gene expression levels. The percentage of patients with baseline or post-therapy alterations in targeted genes will be reported and the association between the occurrence of reversion mutations in DNA repair genes and clinical outcomes will be assessed using logistic regression models for dichotomous endpoints (disease-free state, pCR), and Cox regression or competing risk regression modeling for time-to-event data. Up to 3 years
Primary Maintenance of disease-free state Will be characterized by PSA values sustained below 0.1 ng/ml. A modified intent-to-treat analysis will be conducted. The proportion of patients disease-free at 24 months will be compared in the two treatment arms using a non continuity-corrected chi-square test. As a secondary analysis, a logistic regression model will be fit to adjust for the stratification factors (risk group and type of radiation therapy). Up to 2 years following the start of antiandrogen therapy
Secondary Overall Survival Will consist of comparison of Kaplan-Meier (Kaplan 1958) curves using a logrank test. From randomization until death from any cause, assessed up to 3 years
Secondary Prostate cancer-specific survival Will consist of comparison of Kaplan-Meier (Kaplan 1958) curves using a logrank test. From randomization until death from prostate cancer, assessed up to 3 years
Secondary Pathologic Complete Response (pCR) Will be assessed among patients undergoing 12-core biopsy. Will be compared using a chi-square test. At 24 months
Secondary Time to local/regional or distant progression Cumulative incidence curves will be compared using the Fine-Gray test (Dignam 2008). Up to 3 years
Secondary Time to distant metastases Cumulative incidence curves will be compared using the Fine-Gray test (Dignam 2008). From randomization until detection of distant metastatic disease, assessed up to 3 years
Secondary Biochemical Progression-Free Survival Will be defined as PSA >= 2 ng/ml over the nadir PSA, the presence of local, regional, or distant recurrence, or death from prostate cancer. Will consist of comparison of Kaplan-Meier (Kaplan 1958) curves using a logrank test. Up to 3 years
Secondary Incidence of Adverse Events (Phase II) Adverse event (AE) rates in the two treatment arms will be summarized by time of occurrence (early versus late), type, grade, and attribution to treatment. For each type of AE, the worst grade occurring during the early treatment period, late treatment period, or entire treatment period will be determined. For each time period, treatment group comparisons will be conducted using chi-square or Fisher exact tests. Up to 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03796767 - Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer Phase 2
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT05735223 - A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence N/A
Recruiting NCT04175431 - Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study Phase 2
Completed NCT05197257 - 68Ga-PSMA-11 PET in Patients With Prostate Cancer Phase 3
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Terminated NCT02491411 - Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel N/A
Active, not recruiting NCT02254746 - A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer N/A
Active, not recruiting NCT05496959 - 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study Phase 2
Completed NCT02940262 - Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy Phase 3
Recruiting NCT04391556 - Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma Phase 2
Enrolling by invitation NCT03503643 - Hemi-Gland Cryoablation for Prostate Cancer at UCLA
Recruiting NCT05832086 - Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes Phase 2
Suspended NCT05064111 - Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy
Not yet recruiting NCT04031378 - Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer Phase 2
Recruiting NCT02600156 - Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors N/A
Recruiting NCT05726292 - A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer Phase 2
Recruiting NCT04423211 - Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging Phase 3
Terminated NCT03718338 - Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
Terminated NCT02564549 - MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca N/A